Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

3.75USD
12:26pm EST
Change (% chg)

$-0.03 (-0.79%)
Prev Close
$3.78
Open
$3.80
Day's High
$3.87
Day's Low
$3.69
Volume
25,831
Avg. Vol
48,110
52-wk High
$5.74
52-wk Low
$2.79

Latest Key Developments (Source: Significant Developments)

Chromadex Corporation Reports Q3 Sales Rose 33 Percent To $8.1 Million
Wednesday, 7 Nov 2018 04:01pm EST 

Nov 7 (Reuters) - Chromadex Corp ::ORATION REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.16.Q3 SALES ROSE 33 PERCENT TO $8.1 MILLION.  Full Article

Chromadex, Dartmouth File Patent Infringement Lawsuit Against Elysium Health
Tuesday, 18 Sep 2018 06:30am EDT 

Sept 18 (Reuters) - Chromadex Corp ::CHROMADEX AND DARTMOUTH COLLEGE FILE PATENT INFRINGEMENT LAWSUIT AGAINST ELYSIUM HEALTH.CHROMADEX - COMPLAINT ALLEGES ELYSIUM'S BASIS DIETARY SUPPLEMENT VIOLATES PATENTS.CHROMADEX - CO IS EXCLUSIVE LICENSEE TO COMMERCIALIZE PATENTS THAT COVER COMPOSITIONS CONTAINING ISOLATED NICOTINAMIDE RIBOSIDE HELD BY DARTMOUTH.  Full Article

Chromadex Announces Strategic Partnership With Jiangxi Government
Monday, 17 Sep 2018 06:30am EDT 

Sept 17 (Reuters) - Chromadex Corp ::CHROMADEX ANNOUNCES STRATEGIC PARTNERSHIP FOR AGING RESEARCH WITH JIANGXI GOVERNMENT IN CHINA.CHROMADEX CORP - ANNOUNCED A STRATEGIC PARTNERSHIP WITH JIANGXI PROVINCIAL GOVERNMENT, PEOPLE'S REPUBLIC OF CHINA.  Full Article

Chromadex Corporation Q4 Loss Per Share $0.17
Thursday, 8 Mar 2018 04:01pm EST 

March 8 (Reuters) - Chromadex Corp ::ORATION REPORTS 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.17.Q4 SALES ROSE 69 PERCENT TO $7.5 MILLION.Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION.QTRLY ADJUSTED EBITDA PER SHARE WAS A LOSS OF $0.10.  Full Article

Chromadex Chairman Stephen Allen Will Retire From The Board
Friday, 16 Feb 2018 04:30pm EST 

Feb 16 (Reuters) - Chromadex Corp ::CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS.CHROMADEX CORP - ‍ ALLEN WILL NOT STAND FOR RE-ELECTION AS A DIRECTOR AT CHROMADEX'S 2018 ANNUAL MEETING IN JUNE​.  Full Article

ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln
Monday, 12 Feb 2018 06:30am EST 

Feb 12 (Reuters) - ChromaDex Corp ::ORATION REPORTS PRELIMINARY 2017 RESULTS.SEES Q4 2017 REVENUE ABOUT $7.5 MILLION.SEES FY 2017 REVENUE ABOUT $21.2 MILLION.AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION.‍FOR FULL YEAR 2017, OPERATING LOSS FROM CONTINUING OPERATIONS IS EXPECTED TO BE IN A RANGE OF $16 MILLION TO $17 MILLION​.  Full Article

Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders
Thursday, 14 Dec 2017 05:06pm EST 

Dec 14 (Reuters) - Chromadex Corp ::CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

ChromaDex Q3 loss per share $0.07 from continuing operations
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - ChromaDex Corp ::ChromaDex reports third quarter 2017 financial results.Q3 loss per share $0.07 from continuing operations.Q3 sales rose 55 percent to $6.1 million.  Full Article

Chromadex announces $23 mln private placement of common stock
Monday, 6 Nov 2017 06:30am EST 

Nov 6 (Reuters) - Chromadex Corp :Chromadex announces $23 million private placement of common stock.Chromadex Corp - in connection with investment, co agreed to sell 5.6 million shares of common stock at a per share price of $4.10​.Chromadex Corp - ‍net proceeds of investment expected to provide co added resources to accelerate plans related to nad+ in general, tru niagen in particular​.  Full Article

Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln
Tuesday, 31 Oct 2017 04:59pm EDT 

Oct 31 (Reuters) - Chromadex Corp :Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing.  Full Article